Atricure, Inc. key statistics and ratios
In fiscal 2025, Atricure, Inc. had return on equity of -2.4% and a net margin of -2.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | −30.2% | −6.4% | −8.5% | −10.7% | −14.0% | −15.1% | −21.0% | −21.5% | −15.4% | −10.5% | −15.2% | −23.3% | 18.3% | −14.1% | −7.6% | −9.6% | −2.1% | 1.9% |
| Return on equity | −96.5% | −22.4% | −33.7% | −53.6% | −26.9% | −15.8% | −17.0% | −18.8% | −16.3% | −10.3% | −14.2% | −14.6% | 11.2% | −9.9% | −6.6% | −9.6% | −2.4% | 2.1% |
| Return on assets | — | −11.2% | −16.1% | −22.7% | −15.9% | −12.0% | −12.6% | −12.1% | −9.9% | −6.8% | −7.7% | −7.6% | 7.5% | −7.7% | −5.1% | −7.3% | −1.8% | 1.6% |
| Effective tax rate | — | — | — | — | — | — | — | — | — | — | — | — | 0.4% | — | — | — | — | 12.8% |
| R&D as % of revenue | 20.9% | 19.5% | 18.4% | 17.3% | 16.4% | 17.3% | 19.8% | 23.1% | 19.5% | 17.2% | 17.9% | 20.9% | 17.7% | 17.4% | 18.5% | 20.7% | 18.6% | 17.2% |
| SG&A as % of revenue | 64.4% | 62.8% | 61.9% | 64.2% | 69.6% | 68.4% | 72.3% | 68.6% | 67.0% | 64.2% | 72.4% | 73.0% | 74.6% | 70.0% | 63.4% | 62.6% | 58.2% | 56.8% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Net margin | −6.8% | −12.5% | −5.5% | −4.5% | −0.2% | 1.2% | 0.1% | 5.8% |
| R&D as % of revenue | 18.1% | 28.1% | 18.2% | 21.5% | 17.0% | 17.4% | 17.2% | 17.2% |
| SG&A as % of revenue | 63.2% | 58.1% | 61.5% | 57.6% | 58.3% | 55.8% | 59.9% | 53.7% |
Financial health
- Short-term assets cover short-term liabilities $346m of assets due within a year against $82m of liabilities due within a year.
- Short-term assets cover long-term liabilities $346m short-term assets against $78m of longer-dated liabilities.
- More cash than debt $168m of cash against $61m of debt.
- Debt below 40% of shareholders' equity Debt is 12% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 12% to 12% over five years.
- A year's operating cash flow covers at least 20% of debt $65m of operating cash flow against $61m of debt.
- Operating profit covers interest at least five times over Operating income of $13m against $6m of interest.
Moat
Weak moat
How hard Atricure's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 2 / 20
Cash operating profit has been a median 3.1% of total assets over 10 years.
- Pricing power 20 / 20
Gross margin has been a median 74.7%, moving by 1.4 percentage points (standard deviation) across 10 years.
- Durability 10 / 20
Operating margin has been a median -8.2%; its worst year was -22.0%.
- Cash conversion 2 / 20
Free cash flow was positive in 2 of 10 years, at a median -5.3% of revenue.
- Discipline 6 / 20
The diluted share count rose 9.0% over five years; stock-based pay has been a median 8.5% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Bioventus Inc. statistics
- Transmedics Group, Inc. statistics
- Artivion, Inc. statistics
- Glaukos Corp statistics
- Novocure Ltd statistics
Head to head: ATRC vs BVSATRC vs TMDXAORT vs ATRC
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies